Last reviewed · How we verify
TQB3824 tablets — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TQB3824 tablets (TQB3824 tablets) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TQB3824 tablets TARGET | TQB3824 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TQB3824 tablets CI watch — RSS
- TQB3824 tablets CI watch — Atom
- TQB3824 tablets CI watch — JSON
- TQB3824 tablets alone — RSS
Cite this brief
Drug Landscape (2026). TQB3824 tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/tqb3824-tablets. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab